In this case Kyowa Hakko Kirin will use InveniAi’s technology, dubbed AlphaMeld, to find new uses for drugs already in the pipeline at the Japanese pharma. Kyowa Hakko Kirin signs AI drug R&D ...
Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well. Amgen pays Kyowa $400m upfront for OX40 eczema drug | pharmaphorum Skip to main content ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback